1. Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics takes the No. 1 spot because it is not just another hope-driven biotech penny stock. Trading around $4.10 with a market capitalization of about $1.72 billion, IOVA has one of the strongest commercial stories among low-priced biotech names this June. In a sector filled with companies waiting for trial results, Iovance already has Amtagvi, described as the first FDA-approved T-cell therapy for a solid tumor indication.
That distinction matters. In biotech, the difference between “promising pipeline” and “approved product” is enormous. Many companies spend years trying to reach the FDA approval stage. Iovance has already reached that milestone with a therapy tied to an important area of cancer treatment. T-cell therapy has been one of the most important developments in modern oncology, and bringing that approach into solid tumors gives IOVA a major narrative advantage.
The company reported Q1 2026 total revenue of around $71 million, up about 45% year over year. That is the kind of number that separates Iovance from ordinary penny-stock biotech names. Investors are not just betting on a future announcement. They can now watch revenue growth, treatment adoption, patient demand, and commercial execution. This is why IOVA ranks above the other names on the list. It has a low share price, but the business story is more advanced.
Still, Iovance is not without risk. Dilution remains a concern, and execution matters heavily. Cell therapy is complex. Manufacturing, patient access, treatment centers, reimbursement, and physician adoption can all affect the company’s growth curve. Investors should also remember that biotech stocks with approved therapies can still be volatile if revenue misses expectations or if expenses rise faster than sales.
But among the best biotech penny stocks to buy or watch this June, IOVA offers one of the clearest combinations of price, commercial traction, oncology relevance, and future upside. It fits major search themes like “top biotech penny stocks,” “best NASDAQ biotech stocks under $5,” “oncology penny stocks,” “cell therapy stocks,” “small-cap biotech stocks to buy,” and “healthcare penny stocks with revenue.” More importantly, it has substance behind those keywords.
Iovance earns the No. 1 ranking because it is not merely a speculative science project. It is a commercial-stage biotech company with a first-in-class type of market story, growing revenue, and a position in one of the most important areas of cancer treatment. For investors looking at June’s biotech penny stock landscape, IOVA stands out as the name with the strongest blend of real product traction and upside potential.
READ ALSO: Top 5 Best Biotech Stocks To Watch Now and Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
